Research Studies

Interested in participating in a clinical research trial?

Apply here and we will contact you within two business days!

Select your language

english

Selecciona tu idioma

ESP

What are clinical studies?

Why participate in a clinical study?

Are clinical studies dangerous?

Clinical studies

Adults with Type 2 Diabetes Looking to Lose Weight

Treatment in children (10-18 yrs) with Diabetes Mellitus type II

Migraines in kids

Severe Asthma in Children/Adolescents

Study for Children and Adolescents with Severe Asthma

Study Details

Study Summary

This study was designed to evaluate the efficacy of a new investigational rescue inhaler device for children and adolescents (ages 4-17) with severe asthma. This dry powder inhaler features both a broncodilator (albuterol sulfate) + corticosteroid, and will be compared to a typical rescue inhaler which only contains the broncodilator.

There will be no cost to any participants in the trial. No medical insurance is required, legal status will not be asked for, and compensation may be provided

Inclusion Criteria

  • Ages 4-17
  • Diagnosis of asthma for at least one year
  • At least one DOCUMENTED case of an asthma attack requiring treatment in the past year
  • Not positive for COVID-19 in the last six weeks

Call Us

phone 100

Whatsapp

wp 100
Study Details

Study Details

Treatment in children (10-18 yrs) with Diabetes Mellitus type II

Study Details

Dulaglutide 3.0 mg and 4.5 mg Medication in Children Aged 10 to Under 18 Years With Diabetes Mellitus Type 2

Protecting our children from chronic illnesses like type 2 diabetes is a top priority. This clinical study is evaluating the safety and effectiveness of dulaglutide at doses of 3.0 mg and 4.5 mg in children and adolescents aged 10 to under 18 years.

Dulaglutide is a medication that helps control blood sugar levels and has shown positive results in adults. Now, its effects are being studied in younger patients to improve type 2 diabetes management and reduce long-term complications.

If your child is between 10 and under 18 years old and has been diagnosed with type 2 diabetes, they may be eligible to participate in this study. All study-related medications and procedures will be provided at no cost, and families may be eligible for reimbursement for travel and time.

 

Call Us

phone 100

Whatsapp

wp 100
Study Details

Study Details

Migraines in kids

Study Details

Study Summary

The PERISCOPE Study is researching an investigational product (Ubrogepant oral), for the acute treatment of migraine in children and adolescents.

(Approved for use among adults by the FDA)

There is no cost to you, no insurance is required, and compensation maybe provided. Legal status will not be asked.

Inclusion Criteria

  • Are between the ages of 6 to 17 years old.
  • Have been experiencing migraines for at least 6 months.
  • Experience between 1 to 14  migraine attacks per month.

Call Us

phone 100

Whatsapp

wp 100
Study Details

Study Details

Adults with Type 2 Diabetes Looking to Lose Weight

Study Details

Study Summary

This study is designed to discover the effiacy and determine the ideal dosage of a new GLP-1 drug for Type II Diabetes. The medication in this study is similar to other injectable GLP-1 drugs, such as semaglutide (Ozempic). It is designed to help control blood sugar. Unlike other GLP-1 drugs, the investigational product in this trial is an oral pill, potentially making it easier for the patient. 

There will be no cost to any participants in the trial. No medical insurance is required, legal status will not be asked for, and compensation may be provided. 

Inclusion Criteria

  • Age 18+
  • Diagnosis of Type 2 Diabetes
  • BMI above 23 kg/m^2
  • HbA1c between 7.0-10.5%
  • Currently managing diabetes, whether that be a stable dose of metformin or just with exercise/diet alone
  • Does NOT use insulin
  • Does NOT have diabetic retinopathy

Call Us

phone 100

Whatsapp

wp 100
Study Details

Study Details

Pneumococcal Conjugate Vaccine in Healthy Toddlers 12 - 15 Months of Age

Study Details

Pneumococcal Vaccine (PG4) for Children Aged 12 to 15 Months

Protecting our children from serious illnesses is a top priority. This clinical study is evaluating PG4 Pneumococcal Conjugate Vaccine for children between 12 and 15 months of age. Pneumococcal disease can cause severe infections such as pneumonia, meningitis, and bloodstream infections in young children.

PG4 has proven to be both safe and effective, offering protection against 25 strains of pneumococcus, compared to the previous vaccine, which protects against fewer strains. This vaccine acts as a booster, providing additional protection against the most common strains and helping to maintain long-term immunity.

If your child is between 12 and 15 months old and has not yet received a pneumococcal vaccine, they may be eligible to participate in this study.

All study-related vaccines and procedures will be provided at no cost, and families may be eligible for reimbursement for travel and time.

Call Us

Whatsapp

Can we call you?

We are actively engaging with the local community to understand its unique healthcare needs and collaborating with residents to address health disparities and promote overall well-being.

CONTACT INFORMATION

Office Number: 202-239-0777
Fax Number: 202-849-8814
info@ecrinstitute.com  

Facebook Youtube Instagram